太美医疗科技(02576.HK) 预计,截至2024年12月31日止年度,将录得不超过2.2亿元人民币(下同)亏损净额,而2023年度亏损净额约为3.56亿元,预期亏损净额减少将不少于38%。主要由于集团聚焦核心竞争力产品及提升管理效率,使整体毛利率上升,以及销售开支及研发开支减少。
(ha/da)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.